Edition:
United Kingdom

People: Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

35.68USD
7:28pm GMT
Change (% chg)

$1.52 (+4.45%)
Prev Close
$34.16
Open
$34.35
Day's High
$36.33
Day's Low
$34.09
Volume
563,253
Avg. Vol
810,661
52-wk High
$111.36
52-wk Low
$33.52

Nicholson, John 

Mr. John L Nicholson is Chief Operating Officer, Senior Vice President of the Company. Mr. Nicholson joined the Company as Senior Vice President of Corporate Development and Business Operations in October 2007 and was appointed Senior Vice President and Chief Financial Officer in December 2007 and served as our Chief Financial Officer until June 2016 when he was promoted to Senior Vice President and Chief Operating Officer. Before joining Nektar, Mr. Nicholson spent 18 years in various executive roles at Schering Berlin, Inc., the U.S. management holding company of Bayer Schering Pharma AG, a pharmaceutical company. From 1997 to September 2007, Mr. Nicholson served as Schering Berlin Inc.’s Vice President of Corporate Development and Treasurer. From 2001 to September 2007, he concurrently served as President of Schering Berlin Insurance Co., and from February 2007 through September 2007, he also concurrently served as President of Bayer Pharma Chemicals and Schering Berlin Capital Corp. Mr. Nicholson holds a B.B.A. from the University of Toledo.

Basic Compensation

Total Annual Compensation, USD 1,173,380
Restricted Stock Award, USD 2,958,790
Long-Term Incentive Plans, USD --
All Other, USD 3,698,990
Fiscal Year Total, USD 7,831,160

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 295,000 3,592,860.00
Name Fiscal Year Total

Robert Chess

556,763

Howard Robin

18,097,400

Gilbert Labrucherie

7,780,090

John Nicholson

7,831,160

Jillian Thomsen

--

Stephen Doberstein

7,698,950
As Of  31 Dec 2017